Lung cancer is the leading cause of cancer-related mortality worldwide for both sexes. The prognosis of the disease is still poor despite improvements in the treatment. Therefore, studies on lung cancer now focus on defining new prognostic markers and new targets in the treatment approach. In this study, we compared the serum levels of Caveolin-1, HMGB1, and Endocan, which can be effective in the carcinogenesis steps, to patients with Non-small cell lung carcinoma (NSCLC) and healthy population. Caveolin-1, HMGB1 and Endocan serum levels were investigated using ELISA method.
Caveolin-1 and HMGB1 levels were higher in the patient group than in the control group, whereas the Endocan level was lower in the patient group than in the control group. But there was no statistical significance for the three parameters. In our study, we found no significant difference in terms of Endocan, Caveolin-1 and HMGB1 levels compared to healthy population. The small number of patients is the most important limitation of our study. Nevertheless, we think that the search for a new marker for early diagnosis and treatment of this disease, which is common in the community, should be continued.
